Table 1.
Circulating miRNAs as diagnostic markers for NSCLC.
| Significantly-expressed miNRAs | Scope | Sample | Technique | Normalization | References |
|---|---|---|---|---|---|
| let-7c, miR-152 (down) | 120 NSCLCs vs. 360 HCs | Plasma | qRT-PCR | U6 | Dou et al., 2015 |
| miR-16-5p, miR-17b-5p, miR-19-3p, miR-20a-5p, miR-92-3p (down) miR-15b-5p(up) | Training set: 94 NSCLCs vs. 58HCs, Validation set: 70 NSCLCs vs. 54 HCs | Serum | TaqMan miRNA assays | Absolute quantification | Fan et al., 2015 |
| miR-148/152 family (Down) miR-944, miR-3662 (up) miR-483-5p, miR-193a-3p, miR-25, miR-214 miR-7 (up) | 20 NSCLCs with BPD VS.10 HCs 90 NSCLCs vs. 85 HCs 221 NSCLCs, 161 HCs, 56 with benign nodules | Serum Plasma | RT-qPCR RT-qPCR TaqMan Low Density Array, RT-qPCR | U6 U6 let-7d/g/i trio | Chen et al., 2015; Li et al., 2015; Powrózek et al., 2015 |
| miR-125a-5p, miR-145 miR-146a (up) | 70 NSCLCs vs. 70 HCs | Serum | RT-qPCR | miR-39 | Wang et al., 2015 |
| A panel of 24 miRNAs (Relative expression) | 100 NSCLCs vs. 100 HCs | Plasma | TaqMan MiRNA Arrays | U6snRNA ath-miR-159a | Wozniak et al., 2015 |
| A panel of 8 miRNAs (Relative expression) | 12 NSCLCs vs. 6 HCs | Exosomes | RT-PCR | mir-1228-3p | Giallombardo et al., 2016 |
| miR-429, miR-205, miR-200b, miR-203, miR-125b miR-34b (up) | 38 NSCLCs, 16 patients with COPD, 16 HCs | Serum | TaqMan Low Density Arrays | U6 | Halvorsen et al., 2016 |
NSCLCs, NSCLC patients; HCs, healthy controls; RT-PCR, real-time reverse transcription quantitative polymerase chain reaction; COPD, chronic obstructive pulmonary disease; BPD, benign pulmonary diseases.